Islet Sciences Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Islet Sciences Inc announces positive 12-Week phase 2 clinical results for SGLT2 Inhibitor Remogliflozin Etabonate
Islet Sciences Inc:Positive results from two 12-week phase 2b clinical studies of remogliflozin etabonate in type 2 diabetics.Primary end point was HbA1c with secondary end points of fasting plasma glucose, serum lipids, body weight, safety and tolerability.Remogliflozin etabonate is selective SGLT2 inhibitor indicated for type 2 diabetes and NASH.Both phase 2b studies were multicenter, randomized, double-blind, placebo-controlled, pioglitazone-controlled, parallel-group, dose-ranging.Studies evaluating efficacy, safety, and tolerability of multiple remogliflozin etabonate doses for 12 weeks in treatment-naïve subjects with type 2 diabetes.One study dosed remogliflozin etabonate once-daily and the other dosed remogliflozin etabonate twice-daily over the twelve week study period.
Latest Developments for Islet Sciences Inc
Latest Key Developments in Biotechnology
- European Medicines Agency issues positive opinion, recommends full approval of Pharmacyclics Inc's Imbruvica for treatment of two blood cancers
- CanTx Inc and Novogen Ltd appoints contract manufacturing organizations to produce clinical batches of the experimental anti cancer drug
- Zhongyuan Union Stem Cell Bioengineering Co to set up joint venture
- Applied Genetic Technologies Crop announces pricing of public offering
- Share this
- Digg this